Cape Investment Advisory’s BridgeBio Pharma BBIO Stock Holding History

Cape Investment Advisory’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.13K	Buy	+42	New	+$2.94K	﹤0.01%	1141

Other funds holding BBIO

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return

Amalgamated Bank New York $14.5B AUM 44.3% 1-Year Est. Return

Cape Investment Advisory's BBIO Position: Q2 2026 in Review

Cape Investment Advisory opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 42 shares worth $3.13K. The stake represents ﹤0.01% of the portfolio and ranks #1141 among its holdings.

64 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Cape Investment Advisory held 42 shares of BridgeBio Pharma worth $3.13K as of Q2 2026.
BridgeBio Pharma was a new Cape Investment Advisory position in Q2 2026.
BridgeBio Pharma made up ﹤0.01% of Cape Investment Advisory's portfolio in Q2 2026, its #1141 holding.
64 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Cape Investment Advisory's 13F filing for Q2 2026, filed 23 Jul 2026.